Memorial Hospital Research Laboratories

The Charles Rudin Lab

Research

Charles M. Rudin, MD, PhD
Charles M. Rudin, MD, PhD

Physician-scientist Charles M. Rudin, Chief of the Thoracic Oncology Service, leads research that focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models including patient-derived xenografts. These studies are integrated with early phase clinical trials.

The Charles Rudin Lab Members

Publications Highlights

Rekhtman et al., Chromothripsis-mediated small cell lung carcinoma. Cancer Discov 2024 (DOI: 10.1158/2159-8290.CD-24-0286).

Redin et al., SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing. J Hematol Oncol 2024 (DOI: 10.1186/s13045-024-01572-3).

Quintanal-Villalonga et al., CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradationSignal Transduct Target Ther 2024 (DOI: 10.1038/s41392-024-01908-y).

Rudin et al., Clinical benefit from immunotherapy in patients with SCLC is associated with tumor capacity for antigen presentation. J Thorac Oncol 2023 (DOI: 10.1016/j.jtho.2023.05.008).

View All Publications

People

Charles M. Rudin, MD, PhD

Charles M. Rudin, MD, PhD

  • Physician-scientist Charles Rudin focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models.
  • MD, PhD, University of Chicago Pritzker School of Medicine
[email protected]
Email Address
View physician profile
Physician profile

Members

Fathema Uddin
Graduate Student
Álvaro  Quintanal  Villalonga
Director, Translational Medicine-Oncology in AstraZeneca
Kelly Clarke
Senior Program Manager
Barbara Mello, PhD
Senior Research Assistant
Vidushi Durani
Graduate Student
Graduate Student
Research Technician
Dennis Kinyua
Research Technician
Instructor
Assistant Attending Physician
Postdoctoral Fellow
Parvathy Manoj
Lab Manager
Jorge Nuñez
Graduate Student
Esther Redin Resano
Assistant Member and Lab Co-Director
Postdoctoral Fellow
Salomon Tendler
Assistant Attending Physician
Research Assistant
Viola Allaj
Research Associate, Pfizer Inc.
Metamia Ciampricotti
Medical Science Liaison, Tempus AI
John Poirier
Assistant Professor, Director, Preclinical Therapeutics Program, Perlmutter Cancer Center, NYU Langone Health
Joseph Chan
Assistant Member
Eric Gardner
Postdoctoral Research Fellow, Harold Varmus Lab, WCMC
Christopher Hulton, BS, MS
Senior Scientist, Drug Discovery Biology, Treeline Biosciences, Cambridge, MA
Corrin Wohlhieter
Senior Associate, Clarion Life Sciences
James Laird
Medical Resident, Yale School of Medicine
Pictured: Benjamin Lok
Clinician-Scientist, Princess Margaret Cancer Centre and Assistant Professor of Radiation Oncology, University of Toronto
Nisarg Shah
Lab Manager, University of Pennsylvania
Andrew Chow
Clinical Director in Oncology Early Development, Merck
Postdoctoral Fellow, Rockefeller University
W. Victoria Lai
Senior Global Development, Late Oncology Lung, Astra Zeneca
Hirokazu Taniguchi
Assistant professor, Nagasaki University Hospital, Department of Respiratory Medicine
Rebecca Caeser
Senior Scientist, National Cancer Center, Singapore
Assistant Professor & Clinician Scientist, University of Montreal; Co-Director CHUM Microbiome Centre
Emelie Gezelius
Postdoctoral Fellow
Jaspers Janneke
Technology Transfer Officer, Starfish Innovations
Kenta Kawasaki
Assistant Professor, Keio University, Japan
Michael Liu
Research Technician
Linde Miles
Assistant Professor, University of Cincinnati
Consultant, Boston Consulting Group
Harsha Sridhar
Graduate Student, Francis Crick Institute
Kathryn M. Tully
Scientist 1 at Ratio Therapeutics

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Career Opportunities

Apply now

Get in Touch

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Charles M. Rudin discloses the following relationships and financial interests:

  • AbbVie
    Professional Services and Activities
  • Amgen
    Professional Services and Activities
  • Daiichi Sankyo
    Intellectual Property Rights
  • Earli Inc.
    Equity
  • Novartis Pharmaceuticals Corporation
    Professional Services and Activities
  • Roche
    Professional Services and Activities
  • Treeline Biosciences, Inc.
    Professional Services and Activities

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures